Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer

December 17, 2013

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

"When you have known oncogenes that are already targeted by FDA-approved drugs, it just made sense to look for these oncogenes in other cancers," says Marileila Varella Garcia, PhD, investigator at the CU Cancer Center and professor at the CU School of Medicine.

"By rethinking the way we understand cancers - as their genetic mutations and not just as the sites where they live in the body - we see that a therapy that targets a specific mutation may show benefit in treating any other cancer that shares the same mutation," says Dara Aisner, MD, PhD, investigator at the CU Cancer Center and molecular pathologist at the CU School of Medicine.

In this study, Garcia, Aisner and colleagues used the technique known as fluorescence in situ hybridization (FISH) to test for the oncogenic gene rearrangements in 236 tumor samples of colorectal cancer collected from patients enrolled in a large, Australian clinical trial. The work found one patient carrying the ALK rearrangement, confirming previous findings, and demonstrated the first finding of ROS1 as an oncogenic driver of colorectal cancer - in this case found in 2 of the 236 tumor samples.

"Even though the percentage of colorectal cancer patients with these gene rearrangements is small, the benefit to these few patients could be dramatic. It's worth the work. It's worth following this line of reasoning to its conclusion to see if colorectal cancer patients will also benefit from drugs proved effective in lung cancer," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and assistant professor at the CU School of Medicine.

Surprisingly, these gene alterations tended to co-exist in colorectal tumors along with other molecular alterations -tumors that were positive for ALK rearrangements were also positive for another well-defined molecular alternation known as KRAS; ROS1 mutations occurred in one specimen along with the known, oncogenic mutation, BRAF.

"Conventional wisdom is that one molecular driver alteration exists throughout all tumor cells in a specimen, and that it's mutually exclusive of other alterations. We found that neither of those axioms held true - some tumor regions had different alterations, and even more surprisingly, in some regions both alterations were seen. These findings show that you can find more than one alteration in a single specimen, and that not all cells within a single tumor are necessarily driven by the same oncogene," Aisner says.

The group writes that "identification of ALK and ROS1 oncogenes may open new therapeutic options for CRC," specifically with the class of drugs known as tyrosine-kinase inhibitors (TKIs) shown to "turn off" ALK and ROS1 gene mutations thereby killing or slowing the growth of cancer cells. For example, the drug crizotinib was approved by the FDA in 2011 to treat ALK-positive lung cancer, and this drug or others that are in development to treat ALK+ and ROS1+ cancers may have similar benefit in CRC.

"This is a case in which we have all the background science - we know that when ALK and ROS1 improperly fuse with other genes, the result can be oncogenic. We have drugs that target these oncogenes. And we even have tests to determine who has the gene rearrangements and so should benefit from these drugs. The important piece missing was finding these oncogenes in other cancers, and now we've filled in that piece in colorectal cancer," Aisner says.
-end-


University of Colorado Anschutz Medical Campus

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.